In the January 2010 issue of this journal, we called, by name, 305 health economists to answer, without anonymity, an online interactive questionnaire about the pre-market approval of drugs and devices, and about the existence of a market-failure rationale for the policy. Of those called, 44 individuals participated. Here we summarize their answers to the closed-end questions and provide full transcripts of all the virtual conversations. We do not respond to or evaluate the responses. The 44 respondents come from 12 countries. Most of the respondents hold academic positions, but others are in government, industry, the non-profit health sector, and private research/consultancy.